Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.66 |
| ▸ | CES1 | P23141 | 3/20 | 0.66 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701425 | 1.00 | CES2 (0.66) | CES2CES1CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL7777968 | 0.81 | CES2 (0.76) | CES2CES1CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL8070666 | 0.80 | CES2 (1.00) | CES2CES1CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL15761173 | 0.80 | CES2 (0.47) | CES2CES1L3MBTL1MAPTPOLB | |
| SCHEMBL6701469 | 0.79 | CES2 (0.55) | CES2CES1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6701884 | 0.79 | CES2 (0.55) | CES2CES1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6701474 | 0.79 | CES2 (0.55) | CES2CES1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL8666745 | 0.78 | CES2 (0.63) | CES2CES1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL8666744 | 0.78 | CES2 (0.63) | CES2CES1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL24445679 | 0.77 | CES2 (0.52) | CES2CES1MAPTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2927218-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20040077895-A1 | Process for the preparation of strobilurin intermediates | WADITSCHATKA RUDOLF (CH) | 2004-04-22 | — | — | US | disclosed |
| US-6664422-B1 | Process for the preparation of strobilurin intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-16 | — | — | US | disclosed |
| EP-1137627-A1 | PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES | Bayer Aktiengesellschaft (DE) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034229-A1 | PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-15 | — | — | WO | disclosed |
| US-5786374-A | FUNGICIDES, MICROBIOCIDES | NOVARTIS CORPORATION (US) | 1998-07-28 | — | — | US | disclosed |
| EP-0789692-A1 | BENZISOXAZOLE DERIVATIVES AND PESTICIDAL COMPOSITIONS CONTAINING THEM | Novartis AG (CH) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014305-A1 | BENZISOXAZOLE DERIVATIVES AND PESTICIDAL COMPOSITIONS CONTAINING THEM | NOVARTIS AG (CH) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077895-A1 | Process for the preparation of strobilurin intermediates | TET1, CYP1B1, STS | CES2 1780/4885CES1 1221/4885CYP11B1 140/4885 |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | RTN3, CYCS, ATL3 | CES2 2697/4885CES1 2294/4885CYP11B1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.